This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:diseases:ibd [02.08.2019] – [Research] sallieq | home:diseases:ibd [03.13.2019] – [Research] sallieq | ||
---|---|---|---|
Line 4: | Line 4: | ||
+ | < | ||
===== Introduction ===== | ===== Introduction ===== | ||
Line 33: | Line 33: | ||
* // | * // | ||
- | De Hertogh //et al// provide a [[http:// | + | De Hertogh //et al// provide a thorough review of the " |
< | < | ||
Line 181: | Line 181: | ||
===== Research ===== | ===== Research ===== | ||
+ | |||
+ | Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. | ||
+ | |||
+ | In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity. | ||
Development, | Development, | ||
Line 225: | Line 229: | ||
{{tag> | {{tag> | ||
+ | |||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
- | (({{pubmed> | + | |
+ | (({{pubmed> | ||
+ | |||
broken link http:// | broken link http:// | ||
+ | another, maybe [[http:// | ||
< | < |